MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • In vivo staging of pathology in REM sleep behaviour disorder

    K. Knudsen, T. Fedorova, A. Hansen, M. Sommerauer, M. Otto, K. Svendsen, A. Nahimi, M. Stokholm, N. Pavese, C. Beier, D. Brooks, P. Borghammer (Aarhus, Denmark)

  • Incidence of Parkinson’s disease: Pooled analysis of six high-quality incidence studies with long-term follow-up

    A. Macleod, M. Camacho, J. Evans, C. Williams-Gray, R. Lawson, L. Forsgren, G. Alves, O.B. Tysnes, C. Counsell (Aberdeen, United Kingdom)

  • Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study

    C. Borrue-Fernandez, J. Fernandez- Cuesta, MJ. Abenza Abildua (San Sebastian Reyes, Spain)

  • Incobotulinum toxin type A for the treatment of biceps/triceps co-contraction due to obstetrical brachial plexus lesion

    G. Ianieri, R. Marvulli, G. Gallo (Bari, Italy)

  • Increased Parkin expression in a PARK20 (SYNJ1 mutation) iPSCs-based model

    W. Mandemakers, R. Masius, E. Berger, M. Grochowska, M. Quadri, M. Minneboo, M. Picillo, P. Barone, J. Schwamborn, V. Bonifati (Rotterdam, Netherlands)

  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series

    C. Wang, E. Wang, H. Lei (Tucson, AZ, USA)

  • Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: A Neurologist/Patient Real World Assessment in the US

    K. Rajagopalan, J. Barton, J. Pike (Marlborough, MA, USA)

  • Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

    D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

  • Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

    P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

  • Influence of disease progression on the quality of life of individuals with spinocerebellar ataxia type 10

    L. Santos, M. Zonta, H. Teive, N. Mello, F. Neto, A. Macedo (Curitiba, Brazil)

  • « Previous Page
  • 1
  • …
  • 85
  • 86
  • 87
  • 88
  • 89
  • …
  • 177
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley